We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
04:45 PM
-
Workshop Room45 mins
- Roundtable
-
Workshop Room45 mins
- Roundtable
-
Workshop Room45 mins
- Roundtable
-
Workshop Room45 mins
- Roundtable
-
Workshop Room45 mins
- Roundtable
-
Workshop Room45 mins
- Roundtable
05:45 PM
-
Exhibition Hall105 mins
- Networking Break
09:00 AM
-
Theatre 1&290 mins
- Plenary
Join us for an exciting session where innovative biotech start-ups pitch their groundbreaking ideas and solutions. Watch as they present to a panel of expert investors, who will provide real-time feed ...
10:30 AM
-
Theatre 1&245 mins
- Plenary
From optional to inevitable: Where agentic and analytical AI are already changing discovery and early CGT development and what must be true for AI to become a trusted, default tool rather than a pilot ...
11:15 AM
-
Exhibition Hall30 mins
- Networking Break
11:45 AM
-
Theatre 215 mins
- Operational & Commercial Performance
Capacity solved, complexity exposed: Why increasing CGT manufacturing capacity alone doesn’t unlock commercial success and how variability, flexibility and operational friction now limit real-world ad ... -
Theatre 115 mins
- Cell & Gene Therapy Clinical Pathways
Remission without bespoke manufacturing: What recent European clinical results in aggressive leukaemias show about the true potential of off-the-shelf CAR-T and NK therapies and how this changes assum ...
12:00 PM
-
Theatre 115 mins
- Cell & Gene Therapy Clinical Pathways
Hospitals are the bottleneck and the solution: Why even off-the-shelf cell therapies fail without hospital integration and what practical delivery models are emerging across Europe. Designing delivery ... -
Theatre 215 mins
- Operational & Commercial Performance
12:15 PM
-
Theatre 130 mins
- Cell & Gene Therapy Clinical Pathways
Understanding the AGORA model: How collaborative, hospital-anchored models like AGORA are reshaping access to gene and cell therapies for rare and ultra-rare diseases. We cannot scale without hospital ... -
Theatre 215 mins
- Operational & Commercial Performance
The uncomfortable truth: Where early CMC and manufacturing assumptions quietly inflated cost of goods as programmes moved toward later-stage development and why these issues only surfaced under scale ...
12:30 PM
-
Theatre 215 mins
- Operational & Commercial Performance
Why COGS stays stubbornly high: The recurring technical and operational drivers of cost across CGT programme from starting materials and batch failure rates to logistics and facility utilisation. Wher ...
12:45 PM
-
Theatre 130 mins
- Cell & Gene Therapy Clinical Pathways
Submission-ready’ is not ‘FDA-ready’: What the FDA expects to see in a BLA beyond what typically satisfies EMA or national authorities and where European teams most often underestimate depth across CM ... -
Theatre 230 mins
- Operational & Commercial Performance
The cost equation is breaking :Are allogeneic therapies genuinely approaching a manufacturing inflection point and if so, what does that mean for the long-term viability of autologous models that stil ...
01:15 PM
-
Exhibition Hall75 mins
- Networking Break